The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
4
The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels.
UC Davis Medical Center
Sacramento, California, United States
Yale University School of Medecine
New Haven, Connecticut, United States
Advent Health
Orlando, Florida, United States
Safety and Tolerability Profile (Including Treatment-emergent Adverse Events (TEAE)) - Number of Participants
AEs will be summarized based on the date of onset for the event. Number of treatment-emergent AEs will be provided by SOC and PT, by dose cohort and overall.
Time frame: through primary completion visit, an average of 1 year
Free Serum Cu
Free serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values and changes from baseline.
Time frame: through primary completion visit, an average of 1 year
Total Serum Cu
Total serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values and changes from baseline.
Time frame: through primary completion visit, an average of 1 year
24-hour Urinary Cu
24-hour urinary Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values and changes from baseline.
Time frame: through primary completion visit, an average of 1 year
Serum Ceruloplasmin Activity (Enzymatic Assay)
Serum ceruloplasmin will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values and changes from baseline.
Time frame: through primary completion visit, an average of 1 year
VTX-801 Responder Status
The number of Responders and Insufficient-Responders will be summarized by dose cohort and planned visit, with response to treatment. Responder status was assessed using radiocopper blood PK results and other cold copper parameters if needed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Michigan Health System
Ann Arbor, Michigan, United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Aarhus University Hospital
Aarhus, Denmark
University Hospital Essen
Essen, Germany
Universitätsklinikum Tübingen (UKT)
Tübingen, Germany
Royal Surrey County Hospital
Guildford, Surrey, United Kingdom
Time frame: At Week 12 and Week 36